Mycenax Biotech (4726) — Cash Flow-to-Debt Ratio
Mycenax Biotech (4726) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of NT$-50.35 Million could theoretically repay 0% of its total liabilities (NT$1.69 Billion) in one year. See how much free cash does Mycenax Biotech generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mycenax Biotech Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Mycenax Biotech across 8 annual periods. Also explore how fast is Mycenax Biotech growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Mycenax Biotech (2017–2024)
Year-by-year debt coverage analysis for Mycenax Biotech. For market capitalisation and broader financial context, see Mycenax Biotech market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.14x | NT$-191.68 Million | NT$1.34 Billion | ▼ -43.8% |
| 2023 | -0.10x | NT$-131.18 Million | NT$1.32 Billion | ▲ +11.1% |
| 2022 | -0.11x | NT$-150.19 Million | NT$1.35 Billion | ▲ +6.1% |
| 2021 | -0.12x | NT$-146.23 Million | NT$1.23 Billion | ▼ -136.9% |
| 2020 | 0.32x | NT$174.17 Million | NT$540.89 Million | ▲ +170.0% |
| 2019 | -0.46x | NT$-140.74 Million | NT$306.04 Million | ▲ +46.0% |
| 2018 | -0.85x | NT$-180.27 Million | NT$211.70 Million | ▼ -215.8% |
| 2017 | -0.27x | NT$-45.55 Million | NT$168.93 Million | — |